Weight Loss With Microdose Tirzepatide: Real-World Outcomes in Patients Initiating Treatment Below 2.5 mg Weekly
endocrinology
Quick verdict
Uncontrolled vendor-data study: modest loss (2.2–6.1%) at microdose tirzepatide 1–2 mg/week; transparent but hypothesis-generating, selection-biased.
Summary
This retrospective, single-organization study from the PlexusDx telehealth program describes body-weight change in 60 adults who began compounded injectable tirzepatide below the standard 2.5 mg/week starting dose, at 1 or 2 mg/week. From 274 candidate records, source-level validation and treatment-start adjudication yielded 93 eligible measurements within 14-35, 36-59, and 60-89-day exposure windows; the latest measurement per patient-window gave 84 summaries. Mean loss was 2.18% (95% CI 1.61-2.76) at a median 21 days, 3.58% (2.43-4.72) at 48 days, and 6.10% (4.60-7.60) at 65.5 days; a random-intercept model over all 93 measurements estimated 2.16 percentage points of additional loss per 30 days. Nineteen percent reported any side effect and none reported vomiting, though capture was not systematic. Major limitations: no comparator, self-reported weights, treatment starts verified for only one patient, attrition left later windows with just 19 and 8 patients, no follow-up reaching 90 days, and both authors hold executive roles at the sponsoring company. The authors consistently label results hypothesis-generating; the data cannot support claims that low-dose initiation matches approved regimens.
Review complete
Assessment at a glance
6
risk flags identified
● high 2
● medium 3
● low 1
4 strengths · 5 weaknesses · 5 author questions
AI text signal = Binoculars zero-shot detector score over 20 sampled passages (Fast-DetectGPT co-reported) — absence does not prove human authorship, and a flag does not imply misconduct.
Levels reflect verification complexity — not a quality score. Evolve never rates your paper.
Key claims under review
- Adults initiating compounded tirzepatide at 1–2 mg/week lost a mean 2.18% (14–35 d), 3.58% (36–59 d), and 6.10% (60–89 d) of baseline body weight while remaining at or below 2 mg/week.
- A random-intercept model over all 93 measurements estimates 2.16 additional percentage points of weight loss per 30 days of adjudicated treatment exposure (95% CI 1.69–2.63).
- Patient-reported tolerability at microdose initiation was favorable (19.0% any side effect, 0% vomiting, 98.3% good/excellent overall feeling), though capture was a routine, non-systematic check-in.
- The findings are explicitly hypothesis-generating and, per the authors, support only prospective comparative study — not claims of causality, dose equivalence, or long-term safety.
Strengths
Unusually candid limitation and hedging discipline
Nearly every claim is explicitly scoped: 'hypothesis-generating', 'not a causal treatment effect', Table 2 footnote warning that 84 records represent 60 people, and Discussion text stating results 'should not be used to claim that lower doses are equivalent or superior'. This reporting honesty exceeds typical vendor RWE.
Documented source-record validation and exposure adjudication
The Methods describe a cohort-wide inconsistency screen (weight conflicts, duplicates, source discrepancies), case-level review against forms/notes/orders/shipping records, and a hierarchical treatment-start rule; the authors quantify adjudication uncertainty (only 1/60 starts verified; provider approval preceded adjudicated start by median 6 days) rather than hiding it.
Transparent measurement accounting and sensitivity analyses
Paired within-patient analyses complement the cross-window description
Weaknesses
No comparator of any kind
Severe, plausibly informative attrition
Structural commercial conflict of interest
Exposure timing and weight data are largely estimated
Cleaning rules evolved with outcomes visible
Full Review Report
$1.99 · one-timeUnlock the complete preliminary analysis Evolve produced for this paper.
Report preview
Structured Review: Microdose Tirzepatide Real-World Outcomes (Hastings & Lee, medRxiv 2026)
The remaining sections cover Methodology Assessment, Statistical Evidence, Results & Reproducibility, Limitations & Risks, and Verdict & Recommendations.
- All 4 strengths & 5 weaknesses, analyzed in detail
- 6 risk flags with severity, section & reviewer questions
- Methods & statistical evidence assessment
- 5 questions a peer reviewer would ask
- Full six-dimension evaluation report & recommendations
One-time purchase · this paper only
One-time purchase, this paper only. AI-generated preliminary analysis — not peer review.
Frequently asked questions
How much weight do patients lose starting tirzepatide at 1–2 mg per week (microdosing)?
In this retrospective study of 60 telehealth patients, average loss was about 2.2% of body weight by days 14–35, 3.6% by days 36–59, and 6.1% by days 60–89 while staying at or below 2 mg/week. There was no control group, weights were self-reported, and the later groups had only 19 and 8 patients — so these are hypothesis-generating descriptive numbers, not proof of effectiveness.
Is microdose tirzepatide safe according to this study?
The study provides only weak safety signals: 11 of 58 patients reported any side effect (most often nausea or constipation) and none reported vomiting at a single routine check-in. Capture was one Yes/No export field without severity grading or causality review, the product was a compounded (non-FDA-approved) formulation, and follow-up lasted under 90 days — so safety cannot be established from these data.
Who conducted the study and are there conflicts of interest?
The analysis used records from the PlexusDx telehealth weight-management program. Both authors hold executive roles at PlexusDx (CEO and Medical Director), the company selling the microdose protocol studied; no external funding was reported. The paper is a medRxiv preprint posted September 2026 and has not been certified by peer review.
Should I ask my doctor to start tirzepatide below the standard 2.5 mg dose?
This paper cannot answer that question. Its authors explicitly state the findings support only prospective comparative study — not conclusions about causality, dose equivalence, or long-term safety. Dosing decisions should be made with a clinician under approved labeling, not on the basis of this uncontrolled preprint.
About this review
This is an AI-generated preliminary review by Evolve.Pub, produced from the openly available text of the paper. It is not peer review and does not represent the authors' views. The canonical record of the paper is at the publisher link above.
- Figures 1–3 appear only as captions in the extracted text; visual content (cohort-flow detail, CI plots, individual trajectories) could not be independently examined.
- The metadata abstract was truncated mid-sentence; the review relies on the embedded full text, whose results are consistent with the abstract fragment and internally consistent across Results, Table 2, and Discussion.
- PDF extraction linearized tables and interleaved license boilerplate; Table 1–3 numbers were cross-checked against Results prose and matched.
- Reference list and STROBE self-description were verified from text, but the cited literature itself was not independently checked.
Go deeper on this paper
Wrote a paper? Stress-test it before reviewers do.
Upload your manuscript for the same structured scrutiny — reasoning, statistics, evidence, figures, and reproducibility.